Scientists report breakthrough neurological findings
15 May 2008

Neuroscientists at the Queensland Brain Institute (QBI) have uncovered "a fundamental component" of the brain's regulation of cognitive function.

For the first time, researchers have discovered how new nerve cells are formed in the hippocampus region of the brain, an area associated with learning and memory, presenting potential insight into the prevention of neurodegenerative conditions, such as Alzheimer's.

Commenting on his findings, published in the Journal of Neuroscience, QBI director professor Perry Bartlett said: "Surprisingly, studies have so far failed to identify a resident stem cell population in the hippocampus that's capable of providing the renewable source of these essential nerve cells."

Together with his research colleague Dr Tara Walker, Professor Bartlett was able to identify the resident stem cell in the hippocampus and how it can be activated to produce new neurons.

Dr Walker explained: "These significant advances in determining the molecular regulation of nerve production will also have a major impact on our understanding of more complex areas such as behaviour, cognition, neurological disease and mental illness."

Register now to access our FREE educational libraryLogin and visit the Alzheimer's Disease Knowledge Centre

Print Article    Bookmark

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...